DOTAGA.Glu.(FAPI)2与DO3A.Glu.(FAPI)2的临床前评估及镥-177与铽-161类似物的人体剂量外推
本研究评估了DOTAGA.Glu.(FAPI)2和DO3A.Glu.(FAPI)2作为FAPI靶向诊疗放射性配体前体的性能。用镓-68和镥-177标记后,在FAP+癌相关成纤维细胞及PC3小鼠模型中进行体外、体内和离体研究,并将小鼠剂量数据外推至人体。结果显示所有放射性配体放射化学纯度>98%,对FAP高亲和力(Kd:0.7-0.9 nM),肿瘤摄取高且背景比良好;外推人体吸收剂量显示[177Lu]Lu-DOTAGA.Glu.(FAPI)2多数器官剂量高于[177Lu]Lu-DO3A.Glu.(FAPI)2,而161Tb标记物组织吸收剂量平均比177Lu标记物高约38%。结论支持这两种前体作为FAP表达恶性肿瘤精准诊疗候选物的临床转化潜力。
要点
- DOTAGA.Glu.(FAPI)2和DO3A.Glu.(FAPI)2标记后放射化学纯度>98%,对FAP亲和力高(Kd:0.7-0.9 nM)。
- [68Ga]标记物在PC3小鼠肿瘤摄取高达18-19%I.A./g(3 h p.i.),PET/SPECT/CT显示高肿瘤/背景比。
- 外推人体剂量显示[177Lu]Lu-DOTAGA.Glu.(FAPI)2多数器官吸收剂量高于[177Lu]Lu-DO3A.Glu.(FAPI)2;161Tb标记物组织剂量平均比177Lu高约38%。
核心结论
- DOTAGA.Glu.(FAPI)2和DO3A.Glu.(FAPI)2是有前景的FAP靶向诊疗放射性配体候选物,支持临床转化。
研究设计与样本
- 临床前研究:DOTAGA.Glu.(FAPI)2和DO3A.Glu.(FAPI)2用镓-68和镥-177标记,在FAP+癌相关成纤维细胞及PC3小鼠模型中进行体外、体内和离体评估,并将小鼠剂量数据外推至人体。
主要发现
- 所有放射性配体放射化学纯度>98%,对FAP高亲和力(Kd:0.7-0.9 nM),在癌相关成纤维细胞中快速内化。
- [68Ga]Ga-DOTAGA.Glu.(FAPI)2和[68Ga]Ga-DO3A.Glu.(FAPI)2在PC3小鼠肿瘤摄取高且持续至3 h p.i.(18-19%I.A./g)。
- [177Lu]Lu-DOTAGA.Glu.(FAPI)2和[177Lu]Lu-DO3A.Glu.(FAPI)2在4 h p.i.肿瘤摄取分别为16.2±2.5和15±1.2%IA/g,48 h p.i.分别达5.1±0.1和2.8±0.4%IA/g。
- 所有放射性配体血液滞留低,PET/SPECT/CT成像证实高肿瘤/背景比,摄取模式与PC3小鼠异质性FAP分布的自显影图像相关。
关键数值与推荐
- 放射化学纯度>98%;FAP亲和力Kd:0.7-0.9 nM。
- [68Ga]标记物肿瘤摄取18-19%I.A./g(3 h p.i.)。
- [177Lu]Lu-DOTAGA.Glu.(FAPI)2和[177Lu]Lu-DO3A.Glu.(FAPI)2肿瘤摄取4 h p.i.分别为16.2±2.5和15±1.2%IA/g,48 h p.i.分别为5.1±0.1和2.8±0.4%IA/g。
- 外推人体吸收剂量(Gy/GBq)显示[177Lu]Lu-DOTAGA.Glu.(FAPI)2多数器官高于[177Lu]Lu-DO3A.Glu.(FAPI)2;161Tb标记物组织吸收剂量平均比177Lu标记物高约38%。
临床怎么用
- 这些临床前数据支持DOTAGA.Glu.(FAPI)2和DO3A.Glu.(FAPI)2作为FAP表达恶性肿瘤精准诊疗的候选放射性配体进一步临床研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aims to assess DOTAGA.Glu.(FAPI)2 and DO3A.Glu.(FAPI)2, specifically engineered as precursors for the development of theranostic FAPI-targeted radioligands. METHODS: DOTAGA.Glu.(FAPI)2 and DO3A.Glu.(FAPI)2 were radiolabeled with gallium-68 and lutetium-177, followed by in vitro (lipophilicity, protein binding, saturation, internalization and externalization) studies on FAP+ CAFs. In vivo (biodistribution, metabolic stability, blood kinetics, PET/SPECT/CT imaging) and ex vivo, (autoradiography, immunohistochemistry) conducted on PC3-mice. Murine dosimetry data were extrapolated to human estimates. RESULTS: All radioligands achievied > 98% radiochemical purity, demonstrating high FAP affinity (Kd:0.7-0.9 nM) and rapid internalization in CAFs, with differences in lipophilicity and serum protein binding. In vivo studies, for [68Ga]Ga-DOTAGA.Glu.(FAPI)2 and [68Ga]Ga-DO3A.Glu.(FAPI)2 showed high and sustained tumor uptake up to 3 h p.i. (18-19%I.A./g). For [177Lu]Lu-DOTAGA.Glu.(FAPI)2 and [177Lu]Lu-DO3A.Glu.(FAPI)2 tumor uptake was 16.2 ± 2.5 and 15 ± 1.2% IA/g at 4 h p.i., reaching 5.1 ± 0.1 and 2.8 ± 0.4%IA/g at 48 h, respectively. All radioligands exhibited low blood retention levels. PET/SPECT/CT imaging confirmed high tumor-to-background ratios. Uptake patterns correlate well with autoradiography images of heterogeneous FAP distribution in PC3-mice, while the detection of both murine and human FAP in PC3-tumors was demonstrated through immunohistochemistry. The extrapolated human absorbed dose estimates (Gy/GBq) for [177Lu]Lu-DOTAGA.Glu.(FAPI)2 were generally higher across most organs compared to [177Lu]Lu-DO3A.Glu.(FAPI)2. Human extrapolation of the 161Tb-labeled radioligands delivered on average ~ 38% higher absorbed doses in tissues as compared to their 177Lu-labeled counterparts. CONCLUSION: These results support the potential clinical translation of DOTAGA.Glu.(FAPI)2 and DO3A.Glu.(FAPI)2, as promising candidates for precise diagnosis and treatment of FAP-expressing malignancies.
引用
- Bilinska A, Kumar N, Gnesin S, et al. Preclinical evaluation of DOTAGA.Glu.(FAPI)2 and DO3A.Glu.(FAPI)2 as theranostics with human dosimetry extrapolation to lutetium-177 and terbium-161 analogs. Eur J Nucl Med Mol Imaging. 2025. PMID: 41105225. doi:10.1007/s00259-025-07565-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。